<SEC-DOCUMENT>0001178913-17-003485.txt : 20171228
<SEC-HEADER>0001178913-17-003485.hdr.sgml : 20171228
<ACCEPTANCE-DATETIME>20171228095107
ACCESSION NUMBER:		0001178913-17-003485
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171228
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171228
DATE AS OF CHANGE:		20171228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Integrity Applications, Inc.
		CENTRAL INDEX KEY:			0001506983
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980668934
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54785
		FILM NUMBER:		171277277

	BUSINESS ADDRESS:	
		STREET 1:		19 HA'YAHALOMIM ST
		STREET 2:		P.O. BOX 12163
		CITY:			ASHDOD
		STATE:			L3
		ZIP:			L3 7760049
		BUSINESS PHONE:		972 (8) 675-7878

	MAIL ADDRESS:	
		STREET 1:		19 HA'YAHALOMIM ST
		STREET 2:		P.O. BOX 12163
		CITY:			ASHDOD
		STATE:			L3
		ZIP:			L3 7760049
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zk1720941.htm
<DESCRIPTION>8-K
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.3.3.1
    Copyright 1995 - 2017 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<div id="DSPFPageHeader"></div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; FONT: bold 14pt/1.25 'Times New Roman', Times, serif">UNITED STATES</div>

<div style="TEXT-ALIGN: center; FONT: bold 14pt/1.25 'Times New Roman', Times, serif">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Washington, D.C. 20549</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: center; FONT: bold 14pt/1.25 'Times New Roman', Times, serif">FORM 8-K</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CURRENT REPORT</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Pursuant to Section 13 or 15(d) of the</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Securities Exchange Act of 1934</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Date of Report (Date of earliest event reported):&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>December 28, 2017</u></font></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<table id="z3e7dd991e0ff4a428c7e85a251fc22ca" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold; FONT-STYLE: normal; WIDTH: 100%">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Integrity Applications, Inc.</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Exact name of registrant as specified in its charter)</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<table id="z094192b179f54ad596f9ecaae4ae376a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Delaware</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">0-54785</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">98-0668934</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(State or Other Jurisdiction</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Commission</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(IRS Employer</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">of Incorporation)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 34%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">File Number)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 33%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Identification No.)</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<table id="z0332b4db95fd4a8182b629773a8be91a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">19 Ha&#8217;Yahalomim St., P.O. Box 12163, Ashdod, Israel</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">L3 7760049</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Address of principal executive offices)</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Zip Code)</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Registrant&#8217;s telephone number, including area code:&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>972 (8) 675-7878</u></font></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<table id="za291e076be85469a946424312f6a1f3d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">N/A</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 100%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Former name or former address, if changed since last report)</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<table id="z4163250835684e43bb6db5a5b760a595" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9744;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9744;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9744;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 4%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9744;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 96%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167; 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167; 240.12b-2).</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Emerging growth company&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Section 7 &#8211; Regulation FD</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Item 7.01. Regulation FD Disclosure</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">On&#160;December 28, 2017,&#160;Integrity Applications, Inc.&#160;&#160;(the &#8220;Company&#8221;) published a press release regarding&#160;the entry into an exclusive distribution agreement with MediReva B.V. for its non-invasive glucose monitoring device, GlucoTrack&#174;, in the Netherlands.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">A copy of&#160;the press release&#160;is&#160;attached hereto as&#160;Exhibit&#160;99.1.&#160;The information contained in this item and the&#160;exhibit&#160;attached herewith shall be deemed furnished and not filed.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Section 9 &#8211; Financial Statements and Exhibits</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Item 9.01. Financial Statements and Exhibits</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zb66ba93f5af94579b11349e0fd4cb19c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 7%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Exhibit&#160;No.</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 90%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Description</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="exhibit_99-1.htm">99.1</a></div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM-COLOR: ; WIDTH: 90%; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="exhibit_99-1.htm">Press Release, dated December 28, 2017</a></div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">SIGNATURES</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Date:&#160;December 28, 2017</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<table id="zb496143752b4482d81c0371305f6d9c0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">INTEGRITY APPLICATIONS, INC.&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 23%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 23%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">By:</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;/s/ John Graham</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 23%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Name:&#160; John Graham</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 23%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 3%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 24%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Title:&#160; &#160; Chief Executive Officer</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 23%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.3.3.1
    Copyright 1995 - 2017 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: bold; FONT-STYLE: normal; TEXT-ALIGN: right"><u>Exhibit 99.1</u></div>

<div>
<div id="DSPFPageHeader">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><img src="image00001.jpg"></div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; FONT: bold 12pt/1.25 'Times New Roman', Times, serif">Integrity Applications Signs Distribution Agreement for Its GlucoTrack&#174; </div>

<div style="TEXT-ALIGN: center; FONT: bold 12pt/1.25 'Times New Roman', Times, serif">Non-Invasive Glucose Monitoring Device in the Netherlands</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; FONT: bold italic 12pt/1.25 'Times New Roman', Times, serif">Contract Represents Important First Step in European Re-Launch</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Wilmington, DE and Ashdod, Israel</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> &#8211; </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">December 28</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> 2017 - </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>Integrity Applications, Inc</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> (&#8220;Integrity&#8221;) (OTCQB: IGAP), innovator of </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">GlucoTrack&#174;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, a non-invasive device for measuring glucose levels in people with type 2 diabetes and pre-diabetes, announced today that it has entered into an exclusive distribution agreement with </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>MediReva B.V</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">. for the GlucoTrack&#174; in the Netherlands. According to the </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">International Diabetes Federation</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, as of 2017, there are an estimated number of 970,000 adults living with diabetes in the Netherlands, representing approximately 5</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7% of the adult population.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The agreement became effective on December 22nd, 2017.</font></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">MediReva, a family owned business for almost 40 years, consists of a group of companies focused on home healthcare and the distribution of specialty medical products with extensive experience with blood glucose monitoring and diabetes care.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Paul Ummels, CEO of Medireva, expressed, &#8220;Medireva is one of the leading home care support companies in the Netherlands. We have years of experience in helping patients manage their diabetes and we are excited about bringing GlucoTrack to the marketplace&#8221;.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">MediReva&#8217;s national coverage spans the entire Netherlands, as well as a strong presence in Belgium and Luxembourg.&#160; In addition, MediReva and its management team have close relationships and a demonstrated track record with local key opinion leaders, insurance companies and other reimbursement authorities.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">As part of the agreement, MediReva has committed substantial resources, including the hiring of dedicated sales and customer support staff, exclusively for the distribution of GlucoTrack&#174;.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">David Podwalski, Integrity&#8217;s Chief Commercial Officer, commented, &#8220;This distribution agreement in the Netherlands is a major milestone on our path to commercializing GlucoTrack&#174;.&#160; It represents an important first program in our updated commercial partnering strategy. We are excited to work with MediReva to launch GlucoTrack&#174; in the Netherlands, and we look forward to continuing our efforts in making the device available for patients in markets around the world.&#8221;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Commercialization of GlucoTrack&#174; in Europe is one of Integrity&#8217;s near-term priorities.&#160; An overhaul of the previous commercial strategy has been implemented, including changes to product pricing and positioning, distribution channels and geographic focus.&#160; The Netherlands represents an important first market for creation of a scalable blueprint to be used in other European markets where there are approximately 58 million people living with diabetes, representing approximately 8.8% of the adult population.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><img src="image00001.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">About GlucoTrack&#174;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">GlucoTrack&#174; is a truly non-invasive monitoring device that rapidly measures and displays an individual&#8217;s glucose level in about a minute without finger pricking or any pain. GlucoTrack&#174; features a small sensor that clips to the earlobe and measures the user&#8217;s glucose level using innovative and patented sensor technologies. The measured signals are analyzed using a proprietary algorithm and then a calculated glucose level is displayed on a small handheld device the size of a small mobile phone. The glucose results are stored in the device and used to estimate HbA1c level using a proprietary algorithm. The device can also display glucose values graphically, enabling the user to monitor glucose levels over time.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">GlucoTrack&#174; has received approvals for CE Mark in Europe and from the Ministry of Food and Drug Safety in South Korea for type 2 diabetes and pre-diabetics, and is currently in the early stages of commercialization in Europe, South Korea, and other geographies. GlucoTrack&#174; is expected to begin clinical trials for United States FDA approval. The product is currently experimental in the United States and is limited to investigational use only.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">About Integrity Applications, Inc.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Integrity Applications, Inc. (OTCQB: IGAP) was founded in 2001 and is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed GlucoTrack&#174;, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements in about a minute without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. Integrity Applications Inc. is a Delaware corporation, with headquarters in the United States and an R&amp;D site in Ashdod, Israel. For more information, please visit <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>http://www.integrity-app.com/</u></font> and <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>http://www.glucotrack.com</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Media Contact</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Tamar Lin</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><u>tamarl@integrity-app.com</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">+972.8.675.7878</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Investor Contacts</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Sami Sassoun, CFO</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><u>SamiS@integrity-app.com</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">+972 (8) 675-7878 Ext. 400</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Chiara Russo</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Director, Investor Relations</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">LaVoieHealthScience</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">617-374-8800 Ext. 112</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><u>CRusso@lavoiehealthscience.com</u></div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; WIDTH: 100%; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><img src="image00001.jpg"></div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Forward-Looking Statements</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;expect&#8221;, &#8220;plan&#8221; and &#8220;will&#8221; are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications&#8217; actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications&#8217; results include, but are not limited to, the ability of Integrity Applications to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to its current and future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Integrity Applications&#8217; filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on March 31, 2017.</div>
</div>

<div>&#160;</div>

<div>
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<br>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !F 3@# 2(  A$! Q$!_\0
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M'&X\@ 9]ZZ'PUKFG^)-#M=6T>?S[*Y7=&^,'@X(([$$$$>U &G1110 4444
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M3R..#V.?>ODG]H'P#:> _%-O'I!D&EW\7G11NVXQL#AESW'0C//->]?LJ_\
M)*4_Z_9O_9: );'XZ:#>?$$>&$L[M5:Y-FEZ2-C29V_=ZA2>,_I6;KW[1?AO
M3/$4FGP6-Y>VL,GER7D3*%R#@E5/WA[\9[5\MZ_--;^,M3EM69)UOI2C+U!W
MG&*^B_"O[->DG3K&X\0:I?/=LBR3P6^U$!/)0$@GCIG^5(#L?CAXI\(V?@O3
MIO$NEG6K34&$EG"AV$_+G>'X*\,.G/-6?@]XJ\*77P[N[_P[IS:1INFM(;JV
M(W,A5=Q;/5\KCGKQCM7G7[7MO%9Z#X1MK9!'!"TT<:#HJA8P!^0K1_9"C2;P
M7X@BF19(WO0K(PR&!C&01Z4P/'OCSX[TWQ]XHLM0T>&ZB@M[46Y^T*%+$.S9
M !/&&%>C? ;XO>'_  [X9TGPOJ<-\MTUPZ^>B*T8,DA*]\]QGBN0_:<\.:1X
M:\9:;;:#I\%C!+8B5XX1@%C(XS^0%>J_LX>"O#=_\/\ 2=<O='M)]52>5EN9
M%W,"LAVG!XR,#'':D!I^(/C]X>T7QI/H4]E>20VTYM[B\4KM1P<-A>I .<GV
M. :]B1E=%="&5AD$="*^*/VE/#AT'XG7L\:XMM447L9QQN/#C_OH$_B*^D/A
MOXPCF^"5GK]RX9K"P=9R3U:$%>?<[0?QI@8VO_'SP[HOC:709[2ZD@@F^SSW
MR$;(WSAOEZD ]3[' -%?-OPJT27QK\4M-@NE\U);DW=V2."BG>^?KT_&B@#[
MR=0ZX-9=Q 8F]JU:1@&&",U2E8#$HK0FLP<E#BLB[E>,E8U/^]BM8^]L)LF9
ME09=@OU-59FA=@R. V>>.#5)BS-\V2:DB@D=A@8&>IK11L3*S6IV Z5X9J%H
M@US4)9G7_CYD(7_@1ZU[F.E>.:_82#5+R2$;U:9R1W')K3 VNTSCQU65)1<5
M<I#GD$'Z455(9",AE/TQ5F'S)2!L8D]"!7;*E;5&6'S*,WRU%9_@+4MO!)<S
M+%"C.['  &<UT6E>#[VZVO<E;>(\\\DCV KM]'T6STJ/%LF9,8:1N6/^%<=2
MO&.VK/4*'A7P^NE1>=/AKMQSWV#T'O70T45PRDY.[ *_/6\_Y*)/_P!A1O\
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MQ3'[V,-]1_G-<.)I\KYD>M@:SDO9RZ%RBBBN0[PHHHH **** "BBB@ HHHH
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%HH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
